Latest news with #PatrickBurnett
Yahoo
16-06-2025
- Business
- Yahoo
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced enrolling the first child in its Phase 2 clinical trials called INTEGUMENT-INFANT. The trial aims to test the safety and tolerability of an investigational topical treatment, ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. There are currently very few approved topical or systemic therapies for infants with atopic dermatitis. Atopic dermatitis lifelong chronic condition in children that can impact the entire family by significantly disrupting sleep, increasing the risk of skin infections, and leading to developmental and emotional strain for both the child and caregivers, said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). A biotechnologist working in a laboratory, examining the effects of a Janus Kinase type 1 inhibitor on plaque psoriasis. This INTEGUMENT-INFANT trial builds on previous positive results from the MUSE study, which also evaluated roflumilast cream 0.05% in infants with atopic dermatitis. ZORYVE cream contains roflumilast, a highly potent and selective phosphodiesterase-4 inhibitor designed for topical use. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage dermatology company focused on developing innovative treatments for immune-mediated skin diseases. It develops targeted topical therapies for major inflammatory skin conditions such as atopic dermatitis and alopecia areata. While we acknowledge the potential of ARQT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-06-2025
- Business
- Yahoo
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced enrolling the first child in its Phase 2 clinical trials called INTEGUMENT-INFANT. The trial aims to test the safety and tolerability of an investigational topical treatment, ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. There are currently very few approved topical or systemic therapies for infants with atopic dermatitis. Atopic dermatitis lifelong chronic condition in children that can impact the entire family by significantly disrupting sleep, increasing the risk of skin infections, and leading to developmental and emotional strain for both the child and caregivers, said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). A biotechnologist working in a laboratory, examining the effects of a Janus Kinase type 1 inhibitor on plaque psoriasis. This INTEGUMENT-INFANT trial builds on previous positive results from the MUSE study, which also evaluated roflumilast cream 0.05% in infants with atopic dermatitis. ZORYVE cream contains roflumilast, a highly potent and selective phosphodiesterase-4 inhibitor designed for topical use. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage dermatology company focused on developing innovative treatments for immune-mediated skin diseases. It develops targeted topical therapies for major inflammatory skin conditions such as atopic dermatitis and alopecia areata. While we acknowledge the potential of ARQT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
15-05-2025
- Health
- Associated Press
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
WESTLAKE VILLAGE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the publication of 14 consensus statements from the Genital Psoriasis Wellness Consortium on the impact of genital psoriasis on patients in the Journal of the European Academy of Dermatology and Venereology (JEADV) Clinical Practice. The consensus statements are aimed at providing expert, multidisciplinary guidance in three key areas: (1) physical diagnosis and patient conversations, (2) impact on quality of life and interpersonal relationships, and (3) treatment decisions. 'Despite affecting an estimated six million Americans, genital psoriasis is often underreported and undertreated due to the uniquely sensitive and private nature of the afflicted areas, and uncertainty for how to begin the conversation. Relative to psoriasis in other areas of the body, genital psoriasis also has a greater impact on psychological well-being and quality of life, interpersonal relationships, intimacy, feelings of stigmatization, and rates of depression,' said Jennifer C. Cather, MD, FAAD, Medical Director and Founder of Mindful Dermatology and Modern Research Associates in Dallas, Texas, Genital Psoriasis Consortium member, and manuscript author. 'With the current lack of formal guidelines around genital psoriasis, the goal of convening the Consortium was to bridge the gaps in clinician-patient communication, develop tools and processes that aid in identification and diagnosis, and better-informed shared treatment decisions.' To formulate the consensus statements, a PubMed literature search was conducted, and a total of 78 unique publications were reviewed. Consortium members used a modified Delphi process, including a nominal group technique. The process included two rounds of virtual subcommittee meetings focused on the three key areas, followed by surveys to obtain anonymous feedback, and concluded with a final meeting to discuss and finalize the language of the consensus recommendations. 'Normalizing conversations and improving shared decision-making are critical first steps to improving outcomes. Implementation of the Consortium's new guidelines could provide consistent, streamlined care practices that don't currently exist for this condition,' said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis. 'Arcutis is proud to support the Consortium's efforts to challenge the status quo to improve care for those with genital psoriasis.' Below are the 14 consensus statements outlined in the publication: About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis' unique dermatology development platform coupled with our dermatology expertise allows us to invent differentiated therapies against biologically validated targets, and has produced a robust pipeline with multiple follow-on clinical programs for a range of inflammatory dermatological conditions including atopic dermatitis and alopecia areata. For more information, visit or follow Arcutis on LinkedIn, Facebook, Instagram, and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential real-world use results of ZORYVE foam and the potential for ZORYVE to advance the standard of care in plaque psoriasis, atopic dermatitis and seborrheic dermatitis. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the 'Risk Factors' section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. † Subject to eligibility criteria and maximum program limitation. This offer is not valid for patients without commercial drug insurance or whose prescription claims are eligible to be reimbursed, in whole or in part, by any government program. ‡ Subject to financial eligibility requirements. Other terms and restrictions apply. Contacts: Media Amanda Sheldon, Head of Corporate Communications [email protected] Investors Latha Vairavan, Chief Financial Officer [email protected]
